In contrast, MIE may inhibit IRE1/JNK1 and eIF2α/CHOP pathways, which control energy metabolism, inflammation, and lipid deposition of NAFLD model rats. Here, EIF2A is linked to metabolic dysfunction-associated steatotic liver disease.